

# Azusa Tanimoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5575002/publications.pdf>

Version: 2024-02-01

37  
papers

838  
citations

623574

14  
h-index

501076

28  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1314  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab. <i>Internal Medicine</i> , 2022, 61, 75-79.	0.3	0
2	Multi-institutional survey of thymic carcinoma patients in Hokushin region. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 419-424.	1.2	4
3	Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1153-1158.	1.2	1
4	Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review. <i>Internal Medicine</i> , 2022, 61, 1735-1738.	0.3	3
5	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. <i>Npj Precision Oncology</i> , 2022, 6, 11.	2.3	8
6	Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of <i>NTRK1</i> -rearranged tumor cells. <i>Cancer Science</i> , 2022, 113, 2323-2335.	1.7	5
7	Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis ( <i>TOPGAN2020</i> ). <i>Thoracic Cancer</i> , 2022, 13, 1471-1478.	0.8	5
8	Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 378-383.	0.3	1
9	Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i> -Rearranged/ <i>TP53</i> -Mutant NSCLC via Noxa Expression. <i>Clinical Cancer Research</i> , 2021, 27, 1410-1420.	3.2	24
10	Sarcopenia may Influence the Prognosis in Advanced Thyroid Cancer Patients Treated With Molecular Targeted Therapy. <i>In Vivo</i> , 2021, 35, 401-410.	0.6	5
11	Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass. <i>Internal Medicine</i> , 2021, 60, 409-415.	0.3	1
12	Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1009-1014.	1.0	6
13	Trametinib overcomes <i>KRAS</i> <sup>G12V</sup> -induced osimertinib resistance in a leptomeningeal carcinomatosis model of <i>EGFR</i> -mutant lung cancer. <i>Cancer Science</i> , 2021, 112, 3784-3795.	1.7	12
14	Phase 1/2 study of alectinib in <i>RET</i> -rearranged previously-treated non-small cell lung cancer (ALL-RET). <i>Translational Lung Cancer Research</i> , 2021, 10, 314-325.	1.3	13
15	Cancer among children, adolescents and young adults in the Hokushin region, Japan, between 2010 and 2015. <i>Japanese Journal of Clinical Oncology</i> , 2021, , .	0.6	3
16	A phase I/II study of osimertinib in <i>EGFR</i> exon 20 insertion mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 162, 140-146.	0.9	32
17	<i>MET</i> amplification results in heterogeneous responses to osimertinib in <i>EGFR</i> -mutant lung cancer treated with erlotinib. <i>Cancer Science</i> , 2020, 111, 3813-3823.	1.7	9
18	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing <i>EGFR</i> mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	5.8	69

#	ARTICLE	IF	CITATIONS
19	Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. <i>BMC Cancer</i> , 2020, 20, 156.	1.1	6
20	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 752-765.	0.5	24
21	Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa116.	0.2	2
22	Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. <i>Cancer Science</i> , 2020, 111, 561-570.	1.7	31
23	Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer. <i>Cancer Science</i> , 2020, 111, 2374-2384.	1.7	17
24	Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01). <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 966-971.	0.0	0
25	Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. <i>Journal of Medical Investigation</i> , 2020, 67, 343-350.	0.2	3
26	Aberrant Methylation of Tumor Suppressive miRNAs in Bile from Patients With Pancreaticobiliary Diseases. <i>Anticancer Research</i> , 2019, 39, 5449-5459.	0.5	6
27	Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance. <i>Cancer Science</i> , 2019, 110, 3215-3224.	1.7	32
28	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 947-956.	1.9	14
29	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. <i>Cancer Research</i> , 2019, 79, 1658-1670.	0.4	79
30	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259.	5.8	223
31	Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model. <i>Clinical Cancer Research</i> , 2018, 24, 2357-2369.	3.2	25
32	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 17-25.	1.9	37
33	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. <i>BMC Pulmonary Medicine</i> , 2018, 18, 193.	0.8	12
34	Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3139-3149.	3.2	69
35	In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. <i>Oncotarget</i> , 2017, 8, 73766-73773.	0.8	10
36	Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. <i>Molecular and Clinical Oncology</i> , 2016, 4, 537-540.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. <i>Oncotarget</i> , 2014, 5, 4920-4928.	0.8	46